CO5690571A2 - Combinacion sinergica que comprende roflumilas y (r,r)-formoterol - Google Patents
Combinacion sinergica que comprende roflumilas y (r,r)-formoterolInfo
- Publication number
- CO5690571A2 CO5690571A2 CO05062790A CO05062790A CO5690571A2 CO 5690571 A2 CO5690571 A2 CO 5690571A2 CO 05062790 A CO05062790 A CO 05062790A CO 05062790 A CO05062790 A CO 05062790A CO 5690571 A2 CO5690571 A2 CO 5690571A2
- Authority
- CO
- Colombia
- Prior art keywords
- formoterol
- roflumilas
- combination including
- synergic combination
- synergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- El uso combinado de roflumilast y R,R-formoterol en la prevención de síntomas de, o el tratamiento de una deficiencia del tracto respiratorio en seres humanos.2.- El uso combinado de roflumilast y R,R-formoterol en la prevención de síntomas de, o el tratamiento de una deficiencia del tracto respiratorio en seres humanos, que comprende administrar roflumilast en una dosificación diaria desde 100 hasta 500 µg y R,R-formoterol en una dosificación diaria desde 10 hasta 120 µg.3.- Un medicamento adecuado para el uso combinado de acuerdo con la reivindicación 1 o 2, que comprende roflumilast y R,R-formoterol en combinación fija o libre.4.- El medicamento de acuerdo con la reivindicación 3, que es una combinación fija o libre.5.- El medicamento de acuerdo con la reivindicación 3, que es una combinación fija oral que contiene roflumilast en una dosificación diaria desde 100 hasta 500 µg y R,R-formoterol en una dosificación diaria desde 10 hasta 120 µg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026504 | 2002-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5690571A2 true CO5690571A2 (es) | 2006-10-31 |
Family
ID=32338001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05062790A CO5690571A2 (es) | 2002-11-27 | 2005-06-27 | Combinacion sinergica que comprende roflumilas y (r,r)-formoterol |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20060199865A1 (es) |
| EP (1) | EP1567140B1 (es) |
| JP (1) | JP2006508993A (es) |
| KR (1) | KR20050094810A (es) |
| CN (1) | CN1713902A (es) |
| AT (1) | ATE399544T1 (es) |
| AU (1) | AU2003288169B8 (es) |
| BR (1) | BR0316475A (es) |
| CA (1) | CA2506956C (es) |
| CO (1) | CO5690571A2 (es) |
| CY (1) | CY1110368T1 (es) |
| DE (1) | DE60321954D1 (es) |
| DK (1) | DK1567140T3 (es) |
| EA (1) | EA009990B1 (es) |
| ES (1) | ES2309374T3 (es) |
| HK (1) | HK1081862A1 (es) |
| HR (1) | HRP20050580B1 (es) |
| IL (1) | IL168307A (es) |
| IS (1) | IS2576B (es) |
| MA (1) | MA27538A1 (es) |
| ME (1) | ME00488B (es) |
| MX (1) | MXPA05005438A (es) |
| NO (1) | NO334148B1 (es) |
| NZ (1) | NZ540658A (es) |
| PL (1) | PL214869B1 (es) |
| PT (1) | PT1567140E (es) |
| RS (1) | RS51082B (es) |
| SI (1) | SI1567140T1 (es) |
| TN (1) | TNSN05130A1 (es) |
| UA (1) | UA83017C2 (es) |
| WO (1) | WO2004047828A1 (es) |
| ZA (1) | ZA200503307B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| ME00524B (me) | 2003-03-10 | 2011-10-10 | Astrazeneca Ab | Novi postupak za dobijanje roflumilasta |
| CA2601250C (en) | 2005-03-16 | 2014-10-28 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
| WO2013077830A1 (en) * | 2011-11-25 | 2013-05-30 | Mahmut Bilgic | Synergistilly active combinations of roflumilast and carmoterol |
| CN103784443A (zh) * | 2014-02-18 | 2014-05-14 | 青岛市城阳区人民医院 | 一种包含沙美特罗和罗氟司特的药物组合产品 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| ES2178015T3 (es) * | 1996-11-11 | 2002-12-16 | Sepracor Inc | Procedimiento de preparacion de isomeros de formoterol opticamente puros. |
| CZ293871B6 (cs) * | 1997-02-17 | 2004-08-18 | Altanaápharmaáag | Prostředky pro léčbu ARDS nebo IRDS obsahující @}cyklopropylmethoxyB@N@}@ŹQ@dichloro@pyridinylB@}difluoromethoxyBbenzamid a plicní surfaktant |
| JP2001513097A (ja) * | 1997-02-28 | 2001-08-28 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Ｐｄｅ−抑制物質とアデニル酸シクラーゼ・アゴニストもしくはグアニル酸シクラーゼ・アゴニストとからなる相乗的組み合わせ組成物 |
| US6624181B1 (en) * | 1997-02-28 | 2003-09-23 | Altana Pharma Ag | Synergistic combination |
| MY126544A (en) * | 1998-08-26 | 2006-10-31 | Smithkline Beecham Corp | Therapies for treating pulmonary diseases |
| US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
| DE60043318D1 (de) * | 1999-08-21 | 2010-01-14 | Nycomed Gmbh | Synergistische kombination von pumafentrine und salmeterol |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| DE60224172T2 (de) * | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
| CN1302007C (zh) * | 2001-04-30 | 2007-02-28 | 葛兰素集团有限公司 | 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物 |
-
2003
- 2003-11-26 JP JP2004554476A patent/JP2006508993A/ja active Pending
- 2003-11-26 AU AU2003288169A patent/AU2003288169B8/en not_active Ceased
- 2003-11-26 KR KR1020057009176A patent/KR20050094810A/ko not_active Application Discontinuation
- 2003-11-26 EA EA200500865A patent/EA009990B1/ru not_active IP Right Cessation
- 2003-11-26 MX MXPA05005438A patent/MXPA05005438A/es active IP Right Grant
- 2003-11-26 ES ES03780056T patent/ES2309374T3/es not_active Expired - Lifetime
- 2003-11-26 PT PT03780056T patent/PT1567140E/pt unknown
- 2003-11-26 ME MEP-2008-781A patent/ME00488B/me unknown
- 2003-11-26 US US10/535,817 patent/US20060199865A1/en not_active Abandoned
- 2003-11-26 UA UAA200505965A patent/UA83017C2/uk unknown
- 2003-11-26 AT AT03780056T patent/ATE399544T1/de active
- 2003-11-26 CN CNA2003801036335A patent/CN1713902A/zh active Pending
- 2003-11-26 SI SI200331345T patent/SI1567140T1/sl unknown
- 2003-11-26 RS YUP-2005/0383A patent/RS51082B/sr unknown
- 2003-11-26 EP EP03780056A patent/EP1567140B1/en not_active Expired - Lifetime
- 2003-11-26 DK DK03780056T patent/DK1567140T3/da active
- 2003-11-26 WO PCT/EP2003/013266 patent/WO2004047828A1/en active IP Right Grant
- 2003-11-26 CA CA2506956A patent/CA2506956C/en not_active Expired - Fee Related
- 2003-11-26 DE DE60321954T patent/DE60321954D1/de not_active Expired - Lifetime
- 2003-11-26 BR BR0316475-6A patent/BR0316475A/pt not_active IP Right Cessation
- 2003-11-26 NZ NZ540658A patent/NZ540658A/en not_active IP Right Cessation
- 2003-11-26 PL PL375632A patent/PL214869B1/pl unknown
-
2005
- 2005-04-25 ZA ZA200503307A patent/ZA200503307B/en unknown
- 2005-05-01 IL IL168307A patent/IL168307A/en not_active IP Right Cessation
- 2005-05-10 TN TNP2005000130A patent/TNSN05130A1/en unknown
- 2005-06-16 MA MA28342A patent/MA27538A1/fr unknown
- 2005-06-20 NO NO20053023A patent/NO334148B1/no not_active IP Right Cessation
- 2005-06-20 IS IS7899A patent/IS2576B/is unknown
- 2005-06-20 HR HRP20050580AA patent/HRP20050580B1/hr not_active IP Right Cessation
- 2005-06-27 CO CO05062790A patent/CO5690571A2/es not_active Application Discontinuation
-
2006
- 2006-02-20 HK HK06102227.5A patent/HK1081862A1/xx not_active IP Right Cessation
-
2008
- 2008-09-17 CY CY20081101016T patent/CY1110368T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
| DE60331236D1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
| TNSN05131A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| CO5690571A2 (es) | Combinacion sinergica que comprende roflumilas y (r,r)-formoterol | |
| DK1212072T3 (da) | Farmaceutisk præparat omfattende eukalyptus- og orangeolie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |